Jacquelyn Sumer
Compliance Officer bij CULLINAN THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Jacquelyn Sumer is currently working as the Secretary, Chief Legal & Compliance Officer at Cullinan Oncology, Inc. She previously worked as the Executive Director & Senior Corporate Counsel at Celgene Corp.
from 2017 to 2018.
She also worked as the Vice President & Assistant General Counsel at Bristol Myers Squibb Co. and as the Chief Legal & Compliance Officer at Genocea Biosciences, Inc. Ms. Sumer completed her undergraduate degree at Bucknell University and her graduate degree at Duke University School of Law.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CULLINAN ONCOLOGY, INC.
0.22% | 22-02-2024 | 94 133 ( 0.22% ) | 2 M $ | 31-03-2024 |
Actieve functies van Jacquelyn Sumer
| Bedrijven | Functie | Begin |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Compliance Officer | 15-08-2022 |
Eerdere bekende functies van Jacquelyn Sumer
| Bedrijven | Functie | Einde |
|---|---|---|
| CELGENE | Director/Board Member | 01-07-2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Compliance Officer | - |
Opleiding van Jacquelyn Sumer
| Bucknell University | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
